Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 44 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37wbWlEPTB;MD6wNFY3QSEQvF2= NF\n[|FUSU6JRWK=
MV-4-11 M1nxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMEG1PFYh|ryP NH20fYlUSU6JRWK=
NKM-1 M1\ZS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3VTWM2OD1yLkCxOlk6KM7:TR?= MnrZV2FPT0WU
ML-2 MoPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnntTWM2OD1yLkCxPVg{KM7:TR?= NEnYUWdUSU6JRWK=
BV-173 M{jtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTBwMEKzNVQh|ryP MUPTRW5ITVJ?
RS4-11 NGf4UIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqWXk6UUN3ME2wMlAzPTh5IN88US=> Mm\pV2FPT0WU
HL-60 NWe3S5dbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMEK5NFgh|ryP M3nHZnNCVkeHUh?=
KY821 M3XoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfDO5VrUUN3ME2wMlAzQTd3IN88US=> MUHTRW5ITVJ?
ECC10 NUXScVNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLyUHF4UUN3ME2wMlA{Pzl{IN88US=> NHK1VnVUSU6JRWK=
NCI-H720 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMESwNVEh|ryP NH72RWJUSU6JRWK=
QIMR-WIL NYfuW2NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4roNmlEPTB;MD6wOFI5PyEQvF2= MkfEV2FPT0WU
KG-1 NWntXW1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G2UmlEPTB;MD6wOFQ5PiEQvF2= MXPTRW5ITVJ?
TGW MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwMES2N|Mh|ryP MkHYV2FPT0WU
ATN-1 Ml3YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwMES3N|Mh|ryP NGXON3RUSU6JRWK=
RH-18 Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwME[wOFgh|ryP MnzwV2FPT0WU
EW-18 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYe1bpFYUUN3ME2wMlA3QDRzIN88US=> M33HXXNCVkeHUh?=
NB17 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGzT|N1UUN3ME2wMlA4OTJ2IN88US=> MlHIV2FPT0WU
SK-NEP-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEeyNVMh|ryP NVfyPYlwW0GQR1XS
P12-ICHIKAWA Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnyenFKSzVyPUCuNFc4PzhizszN NVfvT2NtW0GQR1XS
KARPAS-45 NHTt[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknYTWM2OD1yLkC3PFE2KM7:TR?= NYCxZ5NkW0GQR1XS
EW-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;pZ|FKSzVyPUCuNFgxPTNizszN M3[xUHNCVkeHUh?=
NB13 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwMEiyNFMh|ryP MmPjV2FPT0WU
NCI-H209 M2jqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMEi3NFQh|ryP M1rTVHNCVkeHUh?=
NCI-H1092 MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PCb2lEPTB;MD6xNFI4PSEQvF2= MnTCV2FPT0WU
NH-12 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUC3OFQh|ryP NWPvb29PW0GQR1XS
697 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\hZZVPUUN3ME2wMlExQDN7IN88US=> M1:xXnNCVkeHUh?=
KE-37 NFzxbphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTBwMUGzO{DPxE1? NFTZ[IJUSU6JRWK=
MOLT-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPKTWM2OD1yLkG1NVY6KM7:TR?= NH3YNVZUSU6JRWK=
CHP-134 NFLnVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMU[zNFYh|ryP M2HxZXNCVkeHUh?=
D-283MED Ml\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\PZ5ZKSzVyPUCuNVc3QDZizszN M2TncnNCVkeHUh?=
LU-135 Mk\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fUSWlEPTB;MD6xPFU2OiEQvF2= NHuzVJVUSU6JRWK=
LU-134-A M3PqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMUi2O|Eh|ryP MUTTRW5ITVJ?
EM-2 M37Bdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4WwUWlEPTB;MD6xPVkyQCEQvF2= MlTNV2FPT0WU
LU-139 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvvTWM2OD1yLkKwOFk5KM7:TR?= NWjiV4pFW0GQR1XS
ALL-PO MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\rTWM2OD1yLkKxPVg5KM7:TR?= NHu3dXRUSU6JRWK=
NB12 NFP6UopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7lVHlKSzVyPUCuNlMyOTVizszN NYrJUGt5W0GQR1XS
KP-N-YN M3nX[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPjVFZKSzVyPUCuNlM2PzNizszN NHTYNHBUSU6JRWK=
BEN NIjTUGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml:4TWM2OD1yLkKzPVY5KM7:TR?= M1:3THNCVkeHUh?=
HCC1569 NWq4Z4NkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7QUYFDUUN3ME2wMlI2OTB4IN88US=> NX;lTZh7W0GQR1XS
HuO9 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHXTWM2OD1yLkK2O|E2KM7:TR?= NEixd5ZUSU6JRWK=
WM-115 M4LGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzSVmJKSzVyPUCuNlc4OzhizszN MkXvV2FPT0WU
CCRF-CEM MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwM{O1Nlkh|ryP MlXIV2FPT0WU
IST-SL1 MnraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfXc3JKSzVyPUCuN|U{PDNizszN M3H1OXNCVkeHUh?=
BE-13 M1TVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\ncYJKSzVyPUCuN|Y1PTlizszN NFHnWpRUSU6JRWK=
COR-L88 NHzITpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwM{[1OEDPxE1? M1LKVXNCVkeHUh?=
DOHH-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{G1SGlEPTB;MD60NVAzOyEQvF2= M1uyS3NCVkeHUh?=
A704 NUHuTJB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4e0NmlEPTB;MD60NlY4KM7:TR?= M2Xi[XNCVkeHUh?=
KNS-81-FD NH3y[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNESwNVch|ryP Moj2V2FPT0WU
RPMI-8226 M4r1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwNEW2OVIh|ryP NV7oWnJNW0GQR1XS
TGBC24TKB NFPsRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXrTWM2OD1yLkS1O|c5KM7:TR?= MVXTRW5ITVJ?
NCI-H1304 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjNS4xKSzVyPUCuOFYyPTdizszN MVrTRW5ITVJ?
MOLT-13 M13KcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwNE[2NVMh|ryP Mn7mV2FPT0WU
EW-22 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rrUGlEPTB;MD60OlY4OSEQvF2= NXnKblFXW0GQR1XS
MS-1 NInWO3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrTWM2OD1yLkS2PVM{KM7:TR?= NFrIRldUSU6JRWK=
RMG-I MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIdWlEPTB;MD60PVQ3PCEQvF2= NED1OVVUSU6JRWK=
NTERA-S-cl-D1 NHXRTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LnTWlEPTB;MD61NFAyQSEQvF2= MUDTRW5ITVJ?
NCI-H1048 Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvoSFdKSzVyPUCuOVA6PTNizszN NGrG[JlUSU6JRWK=
SW1417 NXjae4lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D2N2lEPTB;MD61OVQ{QCEQvF2= NELIPHJUSU6JRWK=
DB M4rJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3OWJdSUUN3ME2wMlU4ODhizszN NGfBXW1USU6JRWK=
MEG-01 M1K0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXUbG5KSzVyPUCuOVg{OiEQvF2= MlS2V2FPT0WU
EW-13 NV7aNnZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwNUizOFEh|ryP MWHTRW5ITVJ?
LAMA-84 M4XUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ZVGlEPTB;MD61PVIxPyEQvF2= NV:3V|ZrW0GQR1XS
J-RT3-T3-5 M13WNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK3c4JKSzVyPUCuOlA5ODhizszN MWLTRW5ITVJ?
MOLT-16 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTBwNkWyOlQh|ryP MYfTRW5ITVJ?
DU-4475 M4mzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmj0TWM2OD1yLk[1OFI4KM7:TR?= MXzTRW5ITVJ?
HAL-01 NH\BSpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\DeXpKSzVyPUCuO|I2PDlizszN NIXk[FVUSU6JRWK=
RD MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fK[mlEPTB;MD63OVg6QSEQvF2= NGnnbZZUSU6JRWK=
OAW-28 NWrWT40yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDKTWM2OD1yLke4N|ch|ryP MknJV2FPT0WU
HCC38 NGGwUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETiPXNKSzVyPUCuPFAyQSEQvF2= M{\jVXNCVkeHUh?=
NMC-G1 NG\VfXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7ZTWM2OD1yLkixNVIyKM7:TR?= NV\5XldMW0GQR1XS
EW-16 NU\tV4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHpTVVKSzVyPUCuPFE{OjhizszN NVLJOHdxW0GQR1XS
DU-145 NWC2TJVjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D4bWlEPTB;MD64PVkzOyEQvF2= NHzyPGJUSU6JRWK=
HPAF-II MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f4NmlEPTB;MD65NlYzQCEQvF2= M3\WO3NCVkeHUh?=
A427 NIPqXItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfjSJhmUUN3ME2wMlk{ODJ{IN88US=> NH3EcXZUSU6JRWK=
PA-1 NFPGZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDhVpZKSzVyPUCuPVU3PDJizszN MnixV2FPT0WU
OAW-42 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PpOGlEPTB;MD65OlE1PiEQvF2= MlnQV2FPT0WU
L-428 NILqSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIKyRlZKSzVyPUGuNFEzPSEQvF2= MWnTRW5ITVJ?
COLO-824 M3ntc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVO2cmtqUUN3ME2xMlAyPzB6IN88US=> M17LV3NCVkeHUh?=
P30-OHK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nWbmlEPTB;MT6wOFY5QCEQvF2= M1W2RnNCVkeHUh?=
NCI-H2170 MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHGycHhKSzVyPUGuNFYzOyEQvF2= NX6z[I0yW0GQR1XS
HCC2998 M{LSdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKzc|FtUUN3ME2xMlA4OTN3IN88US=> NF33PI5USU6JRWK=
NB14 NGXKeHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwMUO3OFgh|ryP MV;TRW5ITVJ?
TGBC1TKB NGDFeGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETNOnVKSzVyPUGuNVQyPTJizszN MXHTRW5ITVJ?
KP-N-YS MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHoTWM2OD1zLkG2NlM3KM7:TR?= NYjBVXd6W0GQR1XS
CAL-120 M2T6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTOTWM2OD1zLkG2OFI6KM7:TR?= M2\FVXNCVkeHUh?=
SBC-1 M4XDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfyVXJKSzVyPUGuNVkxPTNizszN MYPTRW5ITVJ?
C32 MnfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfGPGdTUUN3ME2xMlE6ODh6IN88US=> NF\IdGZUSU6JRWK=
HCC2157 M4fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HoW2lEPTB;MT6xPVQ6PCEQvF2= M{HtdXNCVkeHUh?=
COLO-792 M1fZd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMkCwO|Eh|ryP M1K3ZnNCVkeHUh?=
ES7 NFGzUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrtW|RKSzVyPUGuNlc6PTFizszN NEnN[2VUSU6JRWK=
HEL NUDBe4xMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwM{GwNlkh|ryP MmTtV2FPT0WU
ES4 M4nwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH70SXNKSzVyPUGuN|Q6QThizszN NIrDZlVUSU6JRWK=
NCI-SNU-1 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXpXFFKSzVyPUGuN|Y2PTVizszN NITSPXRUSU6JRWK=
MDA-MB-415 NYnBVZdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwM{i4OUDPxE1? NUnxOolrW0GQR1XS
NCI-H2342 M2W0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TEcmlEPTB;MT60NFI3QSEQvF2= NYrDOVBqW0GQR1XS
NB69 NHnNOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy4ToNKSzVyPUGuOFYzPzFizszN NEnRT2VUSU6JRWK=
D-247MG NXrBZ|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzYTWM2OD1zLkWxNVIzKM7:TR?= NVq0ZXhZW0GQR1XS
SCC-4 NHWzclVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHWXW1KSzVyPUGuOVk5QDdizszN NHT2fJZUSU6JRWK=
HuH-7 Mof3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEe0TXJKSzVyPUGuOlczQTNizszN MWPTRW5ITVJ?
A388 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrwcHRKSzVyPUGuOlg4OjRizszN MXnTRW5ITVJ?
Calu-3 M2D4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PtO2lEPTB;MT63NFY6PyEQvF2= M3fIeXNCVkeHUh?=
NCI-H1648 NUHhO4Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjXTpJ{UUN3ME2xMlcyPDF6IN88US=> M2TGXXNCVkeHUh?=
NCI-H2052 MkHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\XTWM2OD1zLkeyNlAyKM7:TR?= NWHqd|BnW0GQR1XS
Ramos-2G6-4C10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwN{O2OVYh|ryP MYLTRW5ITVJ?
DEL MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfpTWM2OD1zLke0OlkzKM7:TR?= NUXIfJloW0GQR1XS
SNU-423 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4eyOWlEPTB;MT63PFE2PyEQvF2= NIqzZnNUSU6JRWK=
COR-L23 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHjTWM2OD1zLke5PFc1KM7:TR?= M2KyRXNCVkeHUh?=
OMC-1 M3TmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\KRYd{UUN3ME2xMlg3ODF4IN88US=> MknDV2FPT0WU
EW-11 NXH4UGZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1K3dmlEPTB;MT65OVY2PyEQvF2= NXjWZ4J2W0GQR1XS
HSC-3 M1zYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTFwOU[zOlUh|ryP NHLofGpUSU6JRWK=
MLMA M3TKfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwOU[2O|ch|ryP MVXTRW5ITVJ?
RCM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PLWGlEPTB;Mj6wNFM6QSEQvF2= NXnScGRFW0GQR1XS
MFE-280 M4\zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnuWlZKSzVyPUKuNFI5PDhizszN NXz1cJEyW0GQR1XS
ES8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j3OGlEPTB;Mj6yOVQ4OSEQvF2= MlvKV2FPT0WU
TE-11 M3Hmfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TxcGlEPTB;Mj6yPVQ4OyEQvF2= NFfhdnNUSU6JRWK=
HuO-3N1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G3S2lEPTB;Mj60PFc5KM7:TR?= NUHTOVltW0GQR1XS
MHH-NB-11 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXGbXZqUUN3ME2yMlUyOTV6IN88US=> M3zSfXNCVkeHUh?=
TGBC11TKB NF\IOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwNUe2PFEh|ryP M{fidXNCVkeHUh?=
HOP-92 NIDXR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfPTItKSzVyPUKuOVg4PDNizszN MmHkV2FPT0WU
IGR-1 NXn4[md1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrSfVVGUUN3ME2yMlYzODN3IN88US=> MYfTRW5ITVJ?
GOTO Mn;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XsV2lEPTB;Mj62OVM4PyEQvF2= NHf5V4NUSU6JRWK=
NCI-H1650 NHS1ZVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjvTWM2OD1{LkeyNlE2KM7:TR?= M4\Lb3NCVkeHUh?=
NCI-H1581 NV7ZXZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\RTWM2OD1{Lke5OlgyKM7:TR?= NG\xflJUSU6JRWK=
NCI-H2405 Mnm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLo[3BKSzVyPUKuPFI4QDJizszN Mo\xV2FPT0WU
U-118-MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HqZ2lEPTB;Mj65OlQ6OSEQvF2= M3vJc3NCVkeHUh?=
DoTc2-4510 NGDYVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml33TWM2OD1|LkCxOFE4KM7:TR?= MXHTRW5ITVJ?
NCI-H596 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFz5eGhKSzVyPUOuNFQ6QTdizszN NFPzXGJUSU6JRWK=
MPP-89 M1Hpc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTNwMEW2OlYh|ryP MlvlV2FPT0WU
GCIY M4\ldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf5PYdKSzVyPUOuNlA1QTFizszN NFTCNVJUSU6JRWK=
SW626 NYXNRlQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwMkS1OFMh|ryP NV7SOWxmW0GQR1XS
OCI-AML2 NXHJNXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTNwM{GyO|Ih|ryP NIHtV|ZUSU6JRWK=
NBsusSR MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\qd3ZWUUN3ME2zMlM1QTN6IN88US=> NIfmTllUSU6JRWK=
AN3-CA MkC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH4VWxkUUN3ME2zMlQ1OjN6IN88US=> NWPD[YtOW0GQR1XS
EFM-19 NUXPeGk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfsXnpKSzVyPUOuOFg{OzlizszN MY\TRW5ITVJ?
RVH-421 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xU3lKSzVyPUOuOVY5PzdizszN Mm\YV2FPT0WU
5637 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TmeWlEPTB;Mz62NVExOyEQvF2= Ml75V2FPT0WU
PANC-08-13 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jNW2lEPTB;Mz62N|Q4OiEQvF2= NY\RUJFEW0GQR1XS
H9 M3fGPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTNwNkexOFQh|ryP NUD3V4NCW0GQR1XS
KARPAS-299 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU[wbplHUUN3ME2zMlY4OzZzIN88US=> NF;BTWNUSU6JRWK=
TE-5 M4LheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDB[|VuUUN3ME2zMlcxPzB7IN88US=> MoTPV2FPT0WU
NOS-1 NHPQSGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PkNGlEPTB;Mz63PVg{PCEQvF2= NULDZZBWW0GQR1XS
HH NHrGOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTNwOEO4Olgh|ryP MUDTRW5ITVJ?
769-P MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELzNItKSzVyPUOuPFk2OSEQvF2= M2qxRnNCVkeHUh?=
CHP-212 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HH[mlEPTB;Mz65NlU1QSEQvF2= Mn3SV2FPT0WU
NCI-H82 M1PWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{[0NmlEPTB;Mz65OVk{PiEQvF2= MXzTRW5ITVJ?
Mo-T NF;OUJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV73Nmg4UUN3ME20MlA1OzF{IN88US=> Mnf5V2FPT0WU
BB65-RCC MkKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfzZ4RKSzVyPUSuNFQ{QTlizszN NY[zV3pLW0GQR1XS
SW1990 NFHG[mxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[1TWM2OD12LkC1PVA5KM7:TR?= NEfEbFdUSU6JRWK=
LK-2 M3:5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTRwMUGyPVMh|ryP MlPsV2FPT0WU
ES5 NFXrSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPu[HpzUUN3ME20MlE{QTh3IN88US=> M4XBTXNCVkeHUh?=
JVM-3 NEfhV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3myeWlEPTB;ND6xPFIzOiEQvF2= NHz0RlFUSU6JRWK=
RPMI-7951 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTQTWM2OD12LkKyOFE{KM7:TR?= MWDTRW5ITVJ?
Calu-6 NES3c4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TuUWlEPTB;ND6yO|g5OSEQvF2= NHzxUpNUSU6JRWK=
LC-2-ad MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfYTWM2OD12LkK5OVY5KM7:TR?= NHfsXpVUSU6JRWK=
SW954 M4P6UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1W1fWlEPTB;ND6yPVY3KM7:TR?= M3PxUXNCVkeHUh?=
H-EMC-SS MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnHTWM2OD12LkOxPFMyKM7:TR?= M3H6NnNCVkeHUh?=
ES3 NGfONHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTRwM{W0OFEh|ryP MU\TRW5ITVJ?
no-11 MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDVNpZRUUN3ME20MlM2PTV2IN88US=> MWnTRW5ITVJ?
LAN-6 M4rNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vr[WlEPTB;ND60OVE5QSEQvF2= MX;TRW5ITVJ?
FTC-133 MmW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTRwNUO5OUDPxE1? MX\TRW5ITVJ?
8505C MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfBVXRlUUN3ME20MlU1OjNizszN M{XzdHNCVkeHUh?=
SW620 M3LJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwNUewOVch|ryP MYTTRW5ITVJ?
BCPAP NWO3NYxyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvCTWM2OD12Lk[zOFgyKM7:TR?= NUPq[IlTW0GQR1XS
SK-LU-1 NWPHcoJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7FfWR2UUN3ME20MlY3ODh7IN88US=> M1TIbnNCVkeHUh?=
NCI-H1623 M2jjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Tpd2lEPTB;ND63NFIzQCEQvF2= NEPBXnRUSU6JRWK=
C2BBe1 NH2ySZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXDTWM2OD12Lke0NFA5KM7:TR?= MnGyV2FPT0WU
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTRwN{izPFgh|ryP M{jvbXNCVkeHUh?=
NB6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTRwOE[yNFQh|ryP Ml7QV2FPT0WU
MDA-MB-157 NWfWTGhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmqyTWM2OD12Lki4O|Yh|ryP NYPVPYtYW0GQR1XS
UMC-11 M4LmOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTRwOEi5OlQh|ryP MmLkV2FPT0WU
HCC1419 M1X5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVf5Sop6UUN3ME20MlkxODZ|IN88US=> MWPTRW5ITVJ?
NCI-H2029 NYrnUm4{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH6yfIpKSzVyPUSuPVQyQDVizszN MYfTRW5ITVJ?
LXF-289 M{jaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF33d4hKSzVyPUWuNFM4OTlizszN Mn\rV2FPT0WU
KINGS-1 NVrzPVNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHNTWM2OD13LkC3O|Q1KM7:TR?= NFK1VW1USU6JRWK=
HD-MY-Z MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PmbWlEPTB;NT6yN|k3QSEQvF2= NVfrbHM1W0GQR1XS
ESS-1 NEDnfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILRU4pKSzVyPUWuNlU2QTdizszN M2\4d3NCVkeHUh?=
GI-1 M4LmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nSUWlEPTB;NT6yO|kzPiEQvF2= MlfHV2FPT0WU
RPMI-2650 M1u0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;jZWlEPTB;NT6zOlE3KM7:TR?= M4raR3NCVkeHUh?=
IA-LM Mm\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLpTWM2OD13LkO5PFcyKM7:TR?= NXTWPHdvW0GQR1XS
KP-4 NGDOcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonOTWM2OD13LkS2N|M1KM7:TR?= M{mxbXNCVkeHUh?=
G-402 NVfQbXFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TGSGlEPTB;NT61NVg3PSEQvF2= NHLOfYdUSU6JRWK=
OS-RC-2 MmX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW4TWM2OD13LkWyOlA1KM7:TR?= MVXTRW5ITVJ?
NCI-H1155 MmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vIV2lEPTB;NT61OFk2PSEQvF2= NX\l[WM5W0GQR1XS
OE19 M{C3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjmUVlxUUN3ME21MlY5PjJ2IN88US=> M1eyeXNCVkeHUh?=
U-2-OS MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjZTWM2OD13Lki5NFE{KM7:TR?= MoS5V2FPT0WU
SCC-15 NVfmbFV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX20TJl2UUN3ME21Mlk{PjZ{IN88US=> NHLBR3lUSU6JRWK=
NCI-H630 M2PHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTVwOUm0NFQh|ryP MUjTRW5ITVJ?
PFSK-1 M2eyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTZwMEWyOVkh|ryP NFvHSY1USU6JRWK=
NCI-H1770 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[wTWM2OD14LkKwPFc1KM7:TR?= M3POS3NCVkeHUh?=
SK-MEL-3 M1rP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTZwNEK5NVUh|ryP M3HwfHNCVkeHUh?=
LB1047-RCC NX;wSIo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXvWXBKSzVyPU[uOFc3OjVizszN NWHKTVZGW0GQR1XS
NCI-H446 MlrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTZwNkK5NlUh|ryP NETVNY9USU6JRWK=
SW780 MlzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\GPGlEPTB;Nj63NFE5PSEQvF2= MX\TRW5ITVJ?
NEC8 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTZwN{[2N{DPxE1? MX3TRW5ITVJ?
NOMO-1 M2S1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrjS3MyUUN3ME22Mlc5OTFzIN88US=> NV7zc3NMW0GQR1XS
COLO-668 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZwOESzPFch|ryP NVi0OGdCW0GQR1XS
MC116 NF[3fY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWizRm9lUUN3ME22Mlk{QDl5IN88US=> M4\BXXNCVkeHUh?=
HCC1937 NES4PIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\pNIRKSzVyPU[uPVkzPTFizszN NH\aXmhUSU6JRWK=
NCI-N87 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTHTWM2OD15LkG5Nlk{KM7:TR?= M4L2bXNCVkeHUh?=
COLO-320-HSR MoDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnLemRDUUN3ME23MlIzPzN6IN88US=> M4jJUnNCVkeHUh?=
HCC1806 M2H6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfiNWdEUUN3ME23MlI3ODR2IN88US=> Mn3oV2FPT0WU
OVCAR-3 NFKwTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D5OWlEPTB;Nz6zN|A{QCEQvF2= MV;TRW5ITVJ?
NUGC-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX6SotYUUN3ME23MlM6Pjl2IN88US=> MY\TRW5ITVJ?
SW1783 M2POZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTdwNEOxO|Uh|ryP MXfTRW5ITVJ?
GCT Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvKb41KSzVyPUeuOVY6ODZizszN MlS4V2FPT0WU
NCI-H2126 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zUTGlEPTB;Nz63N|YzPSEQvF2= NF7RTGpUSU6JRWK=
MEL-HO Mnu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTdwN{ewOVQh|ryP M4LjOHNCVkeHUh?=
CAPAN-1 NX3GToU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P5N2lEPTB;Nz63O|M2PyEQvF2= MYjTRW5ITVJ?
SW756 NHnRdW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUSyPHZnUUN3ME23Mlc5OzN|IN88US=> Mk\QV2FPT0WU
SKG-IIIa MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS3XIFKSzVyPUeuPFE5QTJizszN M3zXOXNCVkeHUh?=
HCE-T NX;Bd29FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XJfWlEPTB;Nz64O|c5OyEQvF2= NEnRRoFUSU6JRWK=
Ca-Ski MkLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTdwOUmzPFMh|ryP MVfTRW5ITVJ?
COLO-684 NYizcpllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjhZpJJUUN3ME24MlAyQDF6IN88US=> NEewTpFUSU6JRWK=
KYSE-70 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LicGlEPTB;OD6wO|czQSEQvF2= MX3TRW5ITVJ?
TI-73 Mom0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTrTWM2OD16LkK1PFUyKM7:TR?= NH;zb|lUSU6JRWK=
BT-20 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu4OZBKSzVyPUiuNlYxPTJizszN NFTmZppUSU6JRWK=
MHH-ES-1 MnvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEOxcnBKSzVyPUiuOVE5OzRizszN NI\tPY1USU6JRWK=
TE-12 NETtSllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrkd4pKSzVyPUiuOVk6OzFizszN NUjUXHlbW0GQR1XS
YH-13 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrUZYY5UUN3ME24MlYyODB6IN88US=> MlPTV2FPT0WU
SF126 MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLJWYV{UUN3ME24Mlg{QDZ3IN88US=> MlmwV2FPT0WU
J82 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRThwOUCwN|gh|ryP NED5RWVUSU6JRWK=
RCC10RGB NGHle4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1P2XGlEPTB;OD65PVU3OSEQvF2= M4\wRnNCVkeHUh?=
SK-UT-1 NGP4[45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTlwMES5OFUh|ryP NF2weI9USU6JRWK=
LB2241-RCC NX:yeJNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTlwMUmxN|ch|ryP MXvTRW5ITVJ?
LB996-RCC MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;CVYhOUUN3ME25MlE6QDlizszN MUjTRW5ITVJ?
EPLC-272H M4TI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn6xTWM2OD17LkO3OlU4KM7:TR?= NEDUVYhUSU6JRWK=
CTV-1 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jKNmlEPTB;OT61OlU{OiEQvF2= MVfTRW5ITVJ?
HSC-2 NV:1Z5FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPxTWM2OD17LkW3OVUh|ryP MVfTRW5ITVJ?
SK-MEL-28 M1Xabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DadGlEPTB;OT62NVg6OyEQvF2= MmDhV2FPT0WU
MMAC-SF NIHpUHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3OTWM2OD17Lk[4O|Uh|ryP NFvRV4NUSU6JRWK=
CP50-MEL-B NY[1doRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TyfWlEPTB;OT63OVc5OiEQvF2= NWP1V3oyW0GQR1XS
HT-1080 NFHNNmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nSNmlEPTB;OT63O|c{QSEQvF2= NFT5[4tUSU6JRWK=
HEC-1 MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfSTodKSzVyPUGwMlM{PTJizszN MXrTRW5ITVJ?
AGS MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXwNXpKSzVyPUGwMlM4PCEQvF2= MXzTRW5ITVJ?
GAMG NV3GRXg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPGTWM2OD1zMD61NVYzKM7:TR?= M4rvUnNCVkeHUh?=
SW48 NFe4VlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDlSIpKSzVyPUGwMlUyQDlizszN Mn3nV2FPT0WU
U031 NFrIcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PvU2lEPTB;MUCuOVkxQCEQvF2= MmO1V2FPT0WU
OVCAR-5 Mnr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;5bGlEPTB;MUCuOlQzQSEQvF2= MWLTRW5ITVJ?
SF295 NVf6N29ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTaTWM2OD1zMD62O|A1KM7:TR?= MoHqV2FPT0WU
BHT-101 MlezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjNUnhVUUN3ME2xNE44OTd5IN88US=> MYTTRW5ITVJ?
VMRC-RCZ NYXKb3k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFzLkOyNFEh|ryP M3LZ[XNCVkeHUh?=
ACHN MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nWcWlEPTB;MUGuOFIyOSEQvF2= NIrPZWFUSU6JRWK=
NCI-H526 NX[4SZpRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFzLkWwOFMh|ryP M3HPbnNCVkeHUh?=
MN-60 NFPzeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVO4dJREUUN3ME2xNU42OzlizszN M2LjeXNCVkeHUh?=
NCI-H2291 Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;hWWlEPTB;MUGuOVQ3PiEQvF2= M1;DSnNCVkeHUh?=
SCC-25 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDOTWM2OD1zMT63OVU3KM7:TR?= MkS2V2FPT0WU
SK-MEL-2 M4PQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTFzLke2N|ch|ryP MmThV2FPT0WU
SN12C NVL6blc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojQTWM2OD1zMT65N|U2KM7:TR?= MoX3V2FPT0WU
NCI-H69 NYXER2k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrsUpNKSzVyPUGyMlQzOzRizszN NILrR5lUSU6JRWK=
ME-180 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF{LkewOVQh|ryP NYft[lNMW0GQR1XS
MC-IXC M{nUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF{Lke1NVgh|ryP M{XUNnNCVkeHUh?=
NCI-H2347 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzH[|ZGUUN3ME2xNk44PjF2IN88US=> M2nxXnNCVkeHUh?=
M059J M4PVPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLJV5ExUUN3ME2xNk44PzJ5IN88US=> MVvTRW5ITVJ?
A2058 MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvaTWM2OD1zMj64OlgyKM7:TR?= MonRV2FPT0WU
VA-ES-BJ NXvE[ox7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTF{Lki3PFUh|ryP MnLmV2FPT0WU
Ca9-22 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7NfFBKSzVyPUGyMlk1PTFizszN MV7TRW5ITVJ?
KNS-42 NY\YdHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvrTWM2OD1zMj65PVg1KM7:TR?= MY\TRW5ITVJ?
LoVo Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Trb2lEPTB;MUOuNlMyOyEQvF2= MWLTRW5ITVJ?
AM-38 NWrJO2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\0O25mUUN3ME2xN{4zPTZ4IN88US=> MXLTRW5ITVJ?
NB5 NE\FVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXrVoZKSzVyPUGzMlM4PTJizszN Mnm3V2FPT0WU
L-363 MmjQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHYcZdKSzVyPUGzMlQxOzNizszN M17ZeXNCVkeHUh?=
SK-MEL-30 NGLLflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnkTWM2OD1zND6wOlQ2KM7:TR?= NHHid49USU6JRWK=
NCI-H1563 MojuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF2Lk[wN|kh|ryP NUfROldNW0GQR1XS
NCI-H2228 M2PUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvDTIZKSzVyPUG0MlYxPzdizszN M1nCU3NCVkeHUh?=
MFM-223 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTF3LkG4NVMh|ryP NG\CRphUSU6JRWK=
LB831-BLC NVHXXmZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLWVmtKSzVyPUG1MlI4PjdizszN NX3ScpdxW0GQR1XS
SW872 MonyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXDTWM2OD1zNT6zNFg3KM7:TR?= MWXTRW5ITVJ?
NCI-H522 M4j0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTF3LkOzNFYh|ryP Mn7IV2FPT0WU
EW-1 NFXmZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq0OnJKSzVyPUG1MlU1PjJizszN NFzDbHVUSU6JRWK=
HN MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFu3dm1KSzVyPUG1MlU6PDJizszN MnizV2FPT0WU
SW837 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF3Lke4OFch|ryP Mlf6V2FPT0WU
SCC-9 NWDHZXl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLDTWM2OD1zNT64NVE1KM7:TR?= MmnoV2FPT0WU
MKN7 M2HlWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTVVnpKSzVyPUG1Mlk4OzJizszN NVewR5NkW0GQR1XS
KYSE-410 NVrUdZJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknHTWM2OD1zNj61PVEh|ryP M2LGTXNCVkeHUh?=
SK-N-DZ NGL4VJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF4Lk[xNVYh|ryP NX:1cYwyW0GQR1XS
COR-L105 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P2cGlEPTB;MU[uOlUzQCEQvF2= NFr2OWZUSU6JRWK=
LB2518-MEL NULV[oF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzKZpdKSzVyPUG2Mlg{QDlizszN MX3TRW5ITVJ?
OVCAR-4 M1HzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF4Lki4OlIh|ryP MYTTRW5ITVJ?
TK10 M1\seGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TZSGlEPTB;MU[uPVQ4OyEQvF2= NE\RVGNUSU6JRWK=
KNS-62 NIL1eFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF4Lkm3O|ch|ryP NVrXWZV[W0GQR1XS
RPMI-8866 NYXyOYFsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[wTWM2OD1zNz6xO|MzKM7:TR?= Ml;YV2FPT0WU
HuP-T4 NEjZbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\3bWNKSzVyPUG3MlI1QTVizszN M3LRdXNCVkeHUh?=
CGTH-W-1 M3nqT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrWWFBCUUN3ME2xO{42OjF7IN88US=> NEXSeotUSU6JRWK=
T-24 NVPKOmJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;JfmNKSzVyPUG3MlU{PDdizszN MX;TRW5ITVJ?
HT-3 NGi2TINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH2xZYdKSzVyPUG3MlU6OTRizszN M{Hte3NCVkeHUh?=
KS-1 NYi4WZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF5Lk[3N{DPxE1? M1rqOXNCVkeHUh?=
NCI-H1792 NETafWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF5Lke5PEDPxE1? NX3xdVROW0GQR1XS
ABC-1 MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTMfpZtUUN3ME2xO{45OTRzIN88US=> NGTRV|ZUSU6JRWK=
BPH-1 NVXPT5VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF6LkG2PFUh|ryP MmnoV2FPT0WU
A431 M{nTVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjYWJlOUUN3ME2xPE41OTJ5IN88US=> Ml3vV2FPT0WU
T98G NVfOeVM6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTF6LkWxOVch|ryP MUjTRW5ITVJ?
BHY MmnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLKPG1TUUN3ME2xPE45PjlizszN NIXTN4tUSU6JRWK=
Capan-2 NWrxbm1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDETWM2OD1zOD65NFc5KM7:TR?= MUfTRW5ITVJ?
MDA-MB-175-VII NU\SbmkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF6LkmyNFkh|ryP MWnTRW5ITVJ?
CAL-27 NX7wNFY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\zO41OUUN3ME2xPU4xPDh5IN88US=> M3ryd3NCVkeHUh?=
AsPC-1 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrwTWM2OD1zOT64OlU4KM7:TR?= NX\4OI9RW0GQR1XS
KU812 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi5elRKSzVyPUG5Mlk2PzNizszN M2n0WXNCVkeHUh?=
NCI-H441 MlPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTJyLkCwNUDPxE1? Mli2V2FPT0WU
Mewo NHj4N4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7WOVRKSzVyPUKwMlEzQDhizszN NVvmZoh4W0GQR1XS
SK-MEL-24 NILBWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvT3lsUUN3ME2yNE4yPDd5IN88US=> MYjTRW5ITVJ?
NCI-H727 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXY[WxKSzVyPUKwMlI4ODRizszN MX;TRW5ITVJ?
EKVX NIDwSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7QTWM2OD1{MD62NFYh|ryP NXnYTnY4W0GQR1XS
RT-112 NIXaPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\OZ445UUN3ME2yNE43OTJ{IN88US=> NVzBcmdvW0GQR1XS
CAMA-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH:0XFNKSzVyPUKwMlk5ODNizszN NXHleI5iW0GQR1XS
SW900 NVzzWJB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrmPJJEUUN3ME2yNU4xOTR7IN88US=> MmLmV2FPT0WU
NCI-H23 NFXqV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTmTWM2OD1{MT6xNlc4KM7:TR?= Mn7SV2FPT0WU
SK-PN-DW NGLhSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJzLkG2OFkh|ryP M{nBOnNCVkeHUh?=
BB30-HNC NHryZmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLvTWM2OD1{MT6yO|Q2KM7:TR?= MUDTRW5ITVJ?
VM-CUB-1 M1nhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFOwOm1KSzVyPUKxMlM2OzZizszN NYjDcVd7W0GQR1XS
IST-MEL1 NX\tepZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPlfos2UUN3ME2yNU4{Pjl{IN88US=> NUnTR2wyW0GQR1XS
CTB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvCR4Z3UUN3ME2yNU41PzV3IN88US=> MUDTRW5ITVJ?
LCLC-103H NXjUd5lTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXEemt6UUN3ME2yNk4yPTh{IN88US=> MmjrV2FPT0WU
PANC-03-27 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ{LkWxOlkh|ryP NULlbZplW0GQR1XS
HTC-C3 NV3RXY57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJ{LkW1OVUh|ryP MnrWV2FPT0WU
TE-8 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLlSYJzUUN3ME2yN{4zPTZ3IN88US=> M4e0NXNCVkeHUh?=
NCI-H292 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Pje2lEPTB;MkWuN|U{PiEQvF2= NYP3U3RkW0GQR1XS
COLO-680N MmfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPrO3d2UUN3ME2yOU43OzJ7IN88US=> NWe2eWIyW0GQR1XS
KYSE-520 M2m1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHYTWM2OD1{NT62OFQh|ryP MnTjV2FPT0WU
NB10 MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfYT496UUN3ME2yOk4{OTF5IN88US=> MoDGV2FPT0WU
NCI-H661 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTJ4LkS3NVMh|ryP MWHTRW5ITVJ?
GMS-10 NFjycWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETIbWtKSzVyPUK2Mlg3OzhizszN NV3TS2l6W0GQR1XS
NCI-H2122 Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPNTWM2OD1{Nj65PVk5KM7:TR?= MULTRW5ITVJ?
OVCAR-8 NUXtR3pHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rydWlEPTB;MkeuNFY{QCEQvF2= NHLjb4xUSU6JRWK=
DJM-1 MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\CWGlEPTB;MkeuNVQ2PCEQvF2= MXrTRW5ITVJ?
UACC-893 NVLJW5RGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTJ5Lkm4O|gh|ryP NWXtd3YyW0GQR1XS
C8166 M{LC[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vtfWlEPTB;MkiuOlk{QCEQvF2= NVPvV3diW0GQR1XS
NCI-H1693 NIHQN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLUb5FKSzVyPUK4MlY6PzVizszN M1jqc3NCVkeHUh?=
TYK-nu NGn0fnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjoTWM2OD1|MD6wN|Q2KM7:TR?= NIq4U25USU6JRWK=
SW1710 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3abZpKSzVyPUOwMlEzPiEQvF2= M2K0VXNCVkeHUh?=
A375 NF:1c29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\vO4xKSzVyPUOwMlMzPDNizszN NUHqd4poW0GQR1XS
HMV-II MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7vN5NGUUN3ME2zNU4{PTl{IN88US=> MmD6V2FPT0WU
NCI-H2087 M1fuRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLKTWJzUUN3ME2zNU43OzV{IN88US=> NXzLV|d3W0GQR1XS
CAL-54 MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXnTWM2OD1|MT63NlQyKM7:TR?= MUfTRW5ITVJ?
HCC70 NUPlT|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DaNWlEPTB;M{KuNVM5PyEQvF2= MkDUV2FPT0WU
ES1 M2L2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\YcotKSzVyPUOyMlMxPjJizszN MoH6V2FPT0WU
NCI-H1355 M4O1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfWTlFKSzVyPUOzMlIxPCEQvF2= NYe2ZVdZW0GQR1XS
CFPAC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN|LkKzN|Ih|ryP M4rlWHNCVkeHUh?=
MKN28 NV;PbIpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES0S45KSzVyPUOzMlM5ODlizszN NYjsb5J7W0GQR1XS
HDLM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7lcYRKSzVyPUOzMlY6OzFizszN NIqycFZUSU6JRWK=
PANC-10-05 NFjteIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nRRmlEPTB;M{SuNVAyPCEQvF2= NH7kWopUSU6JRWK=
SAS MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTN2LkS1OlUh|ryP NXW0b5AyW0GQR1XS
HCC1395 M{PwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITKbYRKSzVyPUO0MlcyQDZizszN NGLLfVBUSU6JRWK=
8305C MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3mTWM2OD1|NT64OFE2KM7:TR?= Mm[zV2FPT0WU
KM12 NYDsPZZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn4PI1KSzVyPUO2Mlc2PDdizszN NHHMU|NUSU6JRWK=
SW1116 NGXINVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTwV2RKSzVyPUO3MlU6QTJizszN M1\4d3NCVkeHUh?=
SK-MEL-1 MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHwTWM2OD1|OD6zN|g6KM7:TR?= NYXqTVE6W0GQR1XS
HCC2218 NXnyXGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnBRZVKSzVyPUO4MlY2OTlizszN MXHTRW5ITVJ?
T84 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPaTWM2OD1|OD63OFA6KM7:TR?= M1zC[nNCVkeHUh?=
ETK-1 M4XROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HaUmlEPTB;M{muNFIzKM7:TR?= MlfFV2FPT0WU
COLO-800 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITvZ|lKSzVyPUO5MlM5PjhizszN MXTTRW5ITVJ?
CAL-12T NYThUJU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHXTWM2OD1|OT61NlgyKM7:TR?= MlW1V2FPT0WU
ACN NHzsVXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4[0OmlEPTB;NECuOFkyOSEQvF2= M4S4WnNCVkeHUh?=
SJSA-1 Ml20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PDRWlEPTB;NEGuNVU6PiEQvF2= MoP2V2FPT0WU
PSN1 M3nlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LM[WlEPTB;NEGuNVc1QSEQvF2= MmLUV2FPT0WU
D-566MG MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRzLkKwPFYh|ryP NF7RXYpUSU6JRWK=
EGI-1 NVe5SpQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7ETWM2OD12Mj60Nlgh|ryP NILsUmFUSU6JRWK=
A204 NFOwRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi5TWM2OD12Mj62N|g5KM7:TR?= NVu0U2ZZW0GQR1XS
Saos-2 NV7mPYpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3hZ2c2UUN3ME20Nk45OzZ7IN88US=> MlrNV2FPT0WU
SNU-C2B M2XybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGD6Om1KSzVyPUSzMlY5PzhizszN NYPmTmd6W0GQR1XS
HLE NU\qOZlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4ThT2lEPTB;NESuNFg2PiEQvF2= NGXm[nNUSU6JRWK=
SW1463 NVj2WohxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmS4TWM2OD12ND65PVcyKM7:TR?= MUjTRW5ITVJ?
DSH1 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPvTWM2OD12NT6wNFM{KM7:TR?= M4\WfHNCVkeHUh?=
MCF7 NX;CeVN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzPTWM2OD12NT61NFUyKM7:TR?= MVvTRW5ITVJ?
K5 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL4bXpwUUN3ME20OU46PDB3IN88US=> NEHaRZNUSU6JRWK=
NCI-H358 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f2dGlEPTB;NEeuNlE2KM7:TR?= NYjPUlRCW0GQR1XS
NCI-H2030 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[4UWlEPTB;NEeuNlM4PCEQvF2= MojZV2FPT0WU
SW948 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTR5LkS2OEDPxE1? Mm[4V2FPT0WU
BALL-1 M16wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL1TWM2OD12Nz62NVY5KM7:TR?= M2i3e3NCVkeHUh?=
TE-9 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLIRpRKSzVyPUS3Mlk2QDFizszN NXT2ephlW0GQR1XS
SK-N-FI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXlRWVwUUN3ME20PE4xOzV6IN88US=> MUPTRW5ITVJ?
KALS-1 MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnqfWNKSzVyPUS4MlEzQDlizszN NEj1N2dUSU6JRWK=
HO-1-N-1 MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnoO5BmUUN3ME20PE44PDR3IN88US=> MYfTRW5ITVJ?
NCI-H2452 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXZOWFKSzVyPUS5MlEyPTJizszN MljTV2FPT0WU
OC-314 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTR7Lk[4N|Qh|ryP NGPUPWJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
STAT3 / pSTAT3 / STAT6 / pSTAT6 / Mcl-1 / Cleaved Mcl-1 / Bcl-xl / Bim / puma / Bik / Bax / PARP / c-Myc; 

PubMed: 26811457     


(A) Western blot analysis of expressions of STAT3/p-STAT3 and STAT6/p-STAT6 as well as antiapoptotic members (Bcl-2, Bcl-xL, and Mcl-1) after 48 h of treatments in HDLM-2 cells. (B) Western blot analysis of expressions of proapoptotic proteins (Bim, Puma, Bik, Bax, and p-Bad) as well as caspase cascade molecules (PARP and c-Myc) after 48 h of treatments. β-Actin was used as an input control.

caspase3 / cleaved caspase 3; 

PubMed: 24481442     


(b) (i) N/TERT, (ii) SINCE and (iii) SINEG2 cells were either untreated (0 μM/DMSO) or treated with increasing doses of Navitoclax (ABT-263; 0.025–30 μM) and were incubated for 24 h. Next, cells were collected and whole-cell lysates were prepared and immunoblotted against anti-full-length Caspase 3 (∼35 kDa) antibody, whereas β-actin (∼42 kDa) was used as a protein-loading control. Apoptosis was assessed through detecting the cleaved bands of Caspase-3 (∼19, 17 kDa). 

26811457 24481442
Growth inhibition assay
Cell viability; 

PubMed: 25685063     


(C) Hcc827, (D) H292, and (E) H1993 cells were treated with increasing concentrations of albendazole or mebendazole in the presence of navitoclax (0, 1, 2, and 4 μM). Viability was determined after 1 day.

25685063
In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT03366103 Recruiting Metastatic Malignant Solid Neoplasm|Recurrent Malignant Solid Neoplasm|Recurrent Small Cell Lung Carcinoma|Stage III Small Cell Lung Carcinoma AJCC v7|Stage IIIA Small Cell Lung Carcinoma AJCC v7|Stage IIIB Small Cell Lung Carcinoma AJCC v7|Stage IV Lung Small Cell Carcinoma AJCC v7|Unresectable Solid Neoplasm National Cancer Institute (NCI) November 29 2017 Phase 1|Phase 2
NCT03181126 Recruiting Acute Lymphoblastic Leukemia (ALL)|Lymphoblastic Lymphoma AbbVie November 27 2017 Phase 1
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2
NCT03222609 Recruiting Myelofibrosis (MF) AbbVie October 31 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products4

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID